Listed

Protalix BioTherapeutics, Inc.: Form 10-K for the period ended Dec 31, 2018

Filed with the SEC on Mar 18, 2019 and accepted by EDGAR at Mar 18, 2019, 09:02 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2018-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Cost of revenue12 months2018-01-01 to 2018-12-31$9.3mus-gaap:CostOfRevenue
Research and development12 months2018-01-01 to 2018-12-31$35.5mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative12 months2018-01-01 to 2018-12-31$10.9mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income12 months2018-01-01 to 2018-12-31−$19.3mus-gaap:OperatingIncomeLoss
Net income12 months2018-01-01 to 2018-12-31−$26.5mus-gaap:NetIncomeLoss
Diluted EPS12 months2018-01-01 to 2018-12-31−$0.18us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow12 months2018-01-01 to 2018-12-31−$7.7mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2018-01-01 to 2018-12-31$686.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2018-12-31$37.8mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2018-12-31$53.0mus-gaap:AssetsCurrent
Total assetsAt period end2018-12-31$61.1mus-gaap:Assets
Current liabilitiesAt period end2018-12-31$25.4mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2018-12-31$114.0mus-gaap:Liabilities
Shareholders' equityAt period end2018-12-31−$52.9mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001144204-19-014464. Last ingested by Listed: Nov 10, 2026, 16:48 ET. Listed shows no prices and gives no investment advice.